1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays

 
• By Jung Won Shin

After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.

Uturn
Dong-A Yet To Determine New Development Plans after abbvie u-turn • Source: Alamy

AbbVie Inc. has returned its rights to a MerTK inhibitor program licensed from originator Dong-A ST well over four years ago, marking a setback for the leading South Korean pharma firm’s plan to step up its novel immuno-oncology R&D.

Dong-A ST, an affiliate of Dong-A Socio Holdings , said in a stock market disclosure that it would retain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.

Q3 Korean Biotech Roundup: Obesity News, AimedBio Deal Raise Hopes

 
• By Jung Won Shin

Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.

Topline Phase III Efpeglenatide Data Raise Hopes For Hanmi’s Obesity Contender

 
• By Jung Won Shin

Hanmi is planning to file for Korean approval of the country's first homegrown obesity contender efpeglenatide by year-end, following positive topline Phase III data for the Sanofi U-turned asset.

How Korean Biotech Can Overcome Investment, Regulatory Hurdles

 
• By Jung Won Shin

At recent conferences in Seoul, participants discussed various hurdles for growth in the Korean biotech ecosystem and potential opportunities such as the ongoing collaborations between Korea and Japan.

More from Focus On Asia

Q3 Korean Biotech Roundup: Obesity News, AimedBio Deal Raise Hopes

 
• By Jung Won Shin

Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.

NovaBridge To Move Vabysmo Follower Into Phase III Head-To-Head Trial

 
• By Dexter Jie Yan

On the back of long-term durability data expected from a Phase II study in the fourth quarter, NovaBridge plans to advance VIS-101 into a Phase III head-to-head trial against Roche’s Vabysmo.

‘We Have To Lift Our Game,’ Pfizer Head of R&D Chris Boshoff Tells Galien

 
• By Jessica Merrill

Chinese biopharmaceutical innovation is putting pressure on US drug companies to accelerate R&D, the executive told attendees.